Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LMB-100 |
Synonyms | |
Therapy Description |
LMB-100 is an immunotoxin that targets mesothelin, potentially resulting in antitumor activity (PMID: 27863199, PMID: 32611684). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LMB-100 | RG7787|RO-6927005|RO6927005|LMB100 | LMB-100 is an immunotoxin that targets mesothelin, potentially resulting in antitumor activity (PMID: 27863199, PMID: 32611684). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05375825 | Phase I | LMB-100 | Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin | Withdrawn | USA | 0 |
NCT02810418 | Phase Ib/II | LMB-100 LMB-100 + Nab-paclitaxel | Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | Completed | USA | 0 |
NCT02798536 | Phase I | LMB-100 LMB-100 + Nab-paclitaxel | Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | Completed | USA | 0 |